Clinigen Partners with Tepsivo For Pharmacovigilance Solutions

Clinigen, a worldwide expert in pharmaceutical services, has formed a strategic alliance with Tepsivo, a provider of digital Pharmacovigilance (PV) services. In the framework of the partnership, Clinigen has obtained a minority share in Tepsivo.

Tepsivo's solution utilizes its PV platform along with automated PV software that is driven by artificial intelligence and various digital technologies. The entire PV platform has been created as a unified, integrated system, utilizing Tepsivo’s worldwide network and centralized coordination to offer a more economical and efficient method for managing global PV systems. Tepsivo seeks to assist pharmaceutical and biotechnology clients in various regions to enhance compliance and refine pharmacovigilance operations.

“This strategic partnership reflects our confidence in Tepsivo’s automated pharmacovigilance platform and its ability to modernise pharmacovigilance services,” said Nihad Hasagic, SVP of Strategic Initiatives at Clinigen. “Together, we are not only expanding the range of digital PV solutions available to our clients but also paving the way for a future where technology drives more efficient drug development.” 

Tepsivo co-founder Dominik Hodbod stated, “Tepsivo was designed to transform pharmacovigilance through the integration of digital innovations, such as advanced AI, in all areas of our platform to ensure maximum compliance at minimal cost. Collaborating with Clinigen allows us to speed up our goal of providing cutting-edge digital PV solutions to a worldwide audience, equipping clients with resources that let scientists concentrate on genuine science while enhancing compliance and patient safety.”